Zepp Health Corporation SEC Filings

Form 144 notice for Zepp Health Corp (ZEPP) reports a proposed sale of 3,000 American Depositary Receipts (ADRs) by a person who acquired them as founder shares on 02/08/2018 from the issuer. The filer plans to sell the ADRs through Piper Sandler & Co. on the NYSE, with an aggregate market value listed at $133,590 and an approximate sale date of 09/29/2025.

The filing states there were no other securities sold by the seller in the past three months and includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. The number of ADRs outstanding is reported as 14,591,331, providing context for the size of the proposed sale relative to total shares.

Zepp Health Corporation filed a Form 144/A notifying a proposed sale of 11,000 American Depositary Receipts (ADRs) representing its common stock, with an aggregate market value of $411,070 and approximately 7,173,522 shares outstanding. The proposed approximate date of sale is 09/04/2025 on the NYSE. The ADRs to be sold were acquired on 02/12/2018 through vesting of a restricted stock award from Zepp Health Corporation; the original grant comprised 25,000 shares and payment was recorded as vesting of a restricted share award on the same date. The filer reports no securities sold in the past three months and includes the standard representation that the seller does not possess undisclosed material adverse information.

Zepp Health Corporation Form 144 reports a proposed sale of 44,000 Class A ordinary shares (American depositary shares representing underlying Class A shares) with an aggregate market value of $411,070.00. The shares represent a small portion of the company's outstanding stock of 114,776,364 shares and are planned to be sold on the NYSE with an approximate sale date of 09/04/2025. The filer acquired the securities on 02/12/2018 through stock options that vested on that date. The filing states there were no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Zepp Health Corporation (ZEPP) filing a Form 144 notifies a proposed sale of 1,745 ADRs representing American depositary shares, with an aggregate market value of $60,656.20. The ADRs trade on the NYSE and the filing lists an approximate sale date of 08/27/2025. The securities were acquired through the vesting of restricted share units from Zepp Health between March 2018 and February 2020, and no sales by the holder in the past three months were reported.

Amendment No. 7 to Schedule 13G discloses that FIL Limited, Pandanus Partners, L.P. and Pandanus Associates, Inc. have completely exited their position in Zepp Health Corp (symbol ZEPP). As of the event date 31 Jul 2025, the group reports 0 Class A common shares (CUSIP CIB882000), equating to 0.0 % of the outstanding class. Consequently, the filers now fall below the 5 % reporting threshold. All voting and dispositive powers are reported as 0, and the certification confirms the securities were held in the ordinary course, not to influence control. The filing is signed 06 Aug 2025 by Richard Bourgelas under powers of attorney for each entity.

Allspring Global Investments Holdings, LLC has filed Amendment No. 7 to Schedule 13G declaring its current ownership in Zepp Health Corp (symbol ZEPP) as of 30 June 2025.

• Shares owned: 9,757,152 American Depositary Receipts (ADRs).
• Ownership percentage: 8.7 % of the outstanding ADR class, exceeding the 5 % reporting threshold.
• Voting/dispositive power: Sole voting power and sole dispositive power over the entire position; no shared power reported.
• Holder classification: Designated as a Holding Company/Control person (Item 3 — HC).
• Stake origin: Securities are held for clients of subsidiaries Allspring Global Investments, LLC and Allspring Funds Management, LLC; no single client holds more than 5 % of the class.
• Intent statement: Filing certifies the position was acquired in the ordinary course of business and not to influence control of Zepp Health.
• Signatories & dates: Event date 06-30-2025; filing signed by Senior Compliance Manager Jennifer Grunberg on 07-14-2025.

This disclosure signals a sizeable passive institutional position in Zepp Health, potentially viewed by the market as a vote of confidence in the company’s prospects without implying activist intentions.